SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RECEIPT OF LISTING AND QUOTATION NOTICE FOR NEW SHARES:

A. PROPOSED CONVERSION OF LOAN FROM CATERINE LIMITED INTO NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY ("SHARES"); AND
B. PROPOSED PLACEMENT OF AN AGGREGATE OF 19,748,000 NEW SHARES AT A PLACEMENT PRICE OF S$0.035 PER SHARE TO CERTAIN SUBSCRIBERS

(COLLECTIVELY, THE "PROPOSED TRANSACTIONS")

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcement (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") refers to the Company's announcement dated 30 September 2025 ("**Announcement**") in relation to the following Proposed Transactions:

(i) the proposed conversion of the Loan from Caterine Limited into 149,726,000 new ordinary shares in the capital of the Company ("**Shares**") (the "**Debt Conversion Shares**") (the "**Caterine Debt Conversion**"); and
(ii) the Proposed Placement of an aggregate of 19,748,000 new Shares ("**Placement Shares**") at a placement price of S$0.035 per Share to certain subscribers.

The Board wishes to announce that the Company has on 8 October 2025 received the listing and quotation notice ("**LQN**") from the SGX-ST in respect of the listing of and quotation for the 19,748,000 Placement Shares and the 149,726,000 Debt Conversion Shares, being an aggregate of 169,474,000 new Shares, on the Catalist of the SGX-ST, subject to the Company's compliance with the SGX-ST's listing requirements. The Placement Shares and the Debt Conversion Shares have to be placed out within seven (7) market days from the date of the LQN.

The LQN from the SGX-ST is not to be taken as an indication of the merits of the Placement Shares, the Proposed Placement, the Debt Conversion Shares, the Caterine Debt Conversion, the Company, its subsidiaries and their securities.

The SGX-ST wishes to highlight that in the event that the Company acquires any assets or businesses from the Subscribers, Lender and/or their related parties/associates, the SGX-ST reserves the right to aggregate the acquisitions, the Proposed Placement and Caterine Debt Conversion (as may be applicable) and deem the subsequent asset injections as a very substantial acquisition or reverse takeover under Rule 1015 of the Catalist Rules.

The Company will make further announcement(s) in relation to the Proposed Transactions as and when required.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
9 October 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.